Skip to content
OpenCapital
Get started

abrdn Income Credit Strategies ACP Pharma — Income Loss From Continuing Operations

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$0+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by abrdn Income Credit Strategies in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.

The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about abrdn Income Credit Strategies's pharma — income loss from continuing operations.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is abrdn Income Credit Strategies's pharma — income loss from continuing operations?
abrdn Income Credit Strategies (ACP) reported pharma — income loss from continuing operations of -$7M in Q1 2026.
How has abrdn Income Credit Strategies's pharma — income loss from continuing operations changed year-over-year?
abrdn Income Credit Strategies's pharma — income loss from continuing operations decreased by 250.0% year-over-year, from -$2M to -$7M.
What is the long-term trend for abrdn Income Credit Strategies's pharma — income loss from continuing operations?
Over 3 years (2021 to 2025), abrdn Income Credit Strategies's pharma — income loss from continuing operations has grown at a 10.1% compound annual growth rate (CAGR), from -$3M to -$4M.
What does pharma — income loss from continuing operations mean?
Indicates the net financial result of the Pharma segment's primary business activities, excluding discontinued operations. This figure serves as a primary benchmark for the segment's recurring profitability and operational success. Investors use this to evaluate the sustainability and growth potential of the segment's core business model.